Galanin: Neurobiologic mechanisms and therapeutic potential for Alzheimer's disease

Scott E. Counts, Sylvia E. Perez, Ulrika Kahl, Tamas Bartfai, Robert P. Bowser, Darlene C. Deecher, Deborah C. Mash, Jacqueline Crawley, Elliott J. Mufson

Research output: Contribution to journalArticle

36 Citations (Scopus)

Abstract

The neuropeptide galanin (GAL) is widely distributed in the mammalian CNS. Several lines of evidence suggest that GAL may play a critical role in cognitive processes such as memory and attention through an inhibitory modulation of cholinergic basal forebrain activity. Furthermore, GAL fibers hyperinnervate remaining cholinergic basal forebrain neurons in Alzheimer's disease (AD). This suggests that GAL activity impacts cholinergic dysfunction in advanced AD. Pharmacological and in vitro autoradiographic studies indicate the presence of heterogeneous populations of GAL receptor (GALR) sites in the basal forebrain which bind GAL with both high and low affinity. Interestingly, we have recently observed that GALR binding sites increase in the anterior basal forebrain in latestage AD. Three G protein-coupled GALRs have been identified to date that signal through a diverse array of effector pathways in vitro, including adenylyl cyclase inhibition and phospholipase C activation. The repertoire and distribution of GALR expression in the basal forebrain remains unknown, as does the nature of GAL and GALR plasticity in the AD basal forebrain. Recently, GAL knockout and overexpressing transgenic mice have been generated to facilitate our understanding of GAL activity in basal forebrain function. GAL knockout mice result in fewer cholinergic basal forebrain neurons and memory deficits. On the other hand, mice overexpressing GAL display hyperinnervation of basal forebrain and memory deficits. These data highlight the need to explore further the putative mechanisms by which GAL signaling might be beneficial or deleterious for cholinergic cell survival and activity within basal forebrain. This information will be critical to understanding whether pharmacological manipulation of GALRs would be effective for the amelioration of cognitive deficits in AD.

Original languageEnglish (US)
Pages (from-to)445-470
Number of pages26
JournalCNS Drug Reviews
Volume7
Issue number4
StatePublished - 2001
Externally publishedYes

Fingerprint

Galanin
Alzheimer Disease
Cholinergic Agents
Galanin Receptors
Therapeutics
Memory Disorders
Basal Forebrain
Pharmacology
Neurons
Type C Phospholipases
Neuropeptides
GTP-Binding Proteins
Adenylyl Cyclases
Knockout Mice
Transgenic Mice
Cell Survival
Binding Sites

Keywords

  • Alzheimer's disease
  • Galanin
  • Galanin receptors

ASJC Scopus subject areas

  • Pharmacology
  • Neuropsychology and Physiological Psychology

Cite this

Counts, S. E., Perez, S. E., Kahl, U., Bartfai, T., Bowser, R. P., Deecher, D. C., ... Mufson, E. J. (2001). Galanin: Neurobiologic mechanisms and therapeutic potential for Alzheimer's disease. CNS Drug Reviews, 7(4), 445-470.

Galanin : Neurobiologic mechanisms and therapeutic potential for Alzheimer's disease. / Counts, Scott E.; Perez, Sylvia E.; Kahl, Ulrika; Bartfai, Tamas; Bowser, Robert P.; Deecher, Darlene C.; Mash, Deborah C.; Crawley, Jacqueline; Mufson, Elliott J.

In: CNS Drug Reviews, Vol. 7, No. 4, 2001, p. 445-470.

Research output: Contribution to journalArticle

Counts, SE, Perez, SE, Kahl, U, Bartfai, T, Bowser, RP, Deecher, DC, Mash, DC, Crawley, J & Mufson, EJ 2001, 'Galanin: Neurobiologic mechanisms and therapeutic potential for Alzheimer's disease', CNS Drug Reviews, vol. 7, no. 4, pp. 445-470.
Counts SE, Perez SE, Kahl U, Bartfai T, Bowser RP, Deecher DC et al. Galanin: Neurobiologic mechanisms and therapeutic potential for Alzheimer's disease. CNS Drug Reviews. 2001;7(4):445-470.
Counts, Scott E. ; Perez, Sylvia E. ; Kahl, Ulrika ; Bartfai, Tamas ; Bowser, Robert P. ; Deecher, Darlene C. ; Mash, Deborah C. ; Crawley, Jacqueline ; Mufson, Elliott J. / Galanin : Neurobiologic mechanisms and therapeutic potential for Alzheimer's disease. In: CNS Drug Reviews. 2001 ; Vol. 7, No. 4. pp. 445-470.
@article{dd36d956caa04e38843c702b99e72694,
title = "Galanin: Neurobiologic mechanisms and therapeutic potential for Alzheimer's disease",
abstract = "The neuropeptide galanin (GAL) is widely distributed in the mammalian CNS. Several lines of evidence suggest that GAL may play a critical role in cognitive processes such as memory and attention through an inhibitory modulation of cholinergic basal forebrain activity. Furthermore, GAL fibers hyperinnervate remaining cholinergic basal forebrain neurons in Alzheimer's disease (AD). This suggests that GAL activity impacts cholinergic dysfunction in advanced AD. Pharmacological and in vitro autoradiographic studies indicate the presence of heterogeneous populations of GAL receptor (GALR) sites in the basal forebrain which bind GAL with both high and low affinity. Interestingly, we have recently observed that GALR binding sites increase in the anterior basal forebrain in latestage AD. Three G protein-coupled GALRs have been identified to date that signal through a diverse array of effector pathways in vitro, including adenylyl cyclase inhibition and phospholipase C activation. The repertoire and distribution of GALR expression in the basal forebrain remains unknown, as does the nature of GAL and GALR plasticity in the AD basal forebrain. Recently, GAL knockout and overexpressing transgenic mice have been generated to facilitate our understanding of GAL activity in basal forebrain function. GAL knockout mice result in fewer cholinergic basal forebrain neurons and memory deficits. On the other hand, mice overexpressing GAL display hyperinnervation of basal forebrain and memory deficits. These data highlight the need to explore further the putative mechanisms by which GAL signaling might be beneficial or deleterious for cholinergic cell survival and activity within basal forebrain. This information will be critical to understanding whether pharmacological manipulation of GALRs would be effective for the amelioration of cognitive deficits in AD.",
keywords = "Alzheimer's disease, Galanin, Galanin receptors",
author = "Counts, {Scott E.} and Perez, {Sylvia E.} and Ulrika Kahl and Tamas Bartfai and Bowser, {Robert P.} and Deecher, {Darlene C.} and Mash, {Deborah C.} and Jacqueline Crawley and Mufson, {Elliott J.}",
year = "2001",
language = "English (US)",
volume = "7",
pages = "445--470",
journal = "CNS Drug Reviews",
issn = "1080-563X",
publisher = "Neva Press, Inc.",
number = "4",

}

TY - JOUR

T1 - Galanin

T2 - Neurobiologic mechanisms and therapeutic potential for Alzheimer's disease

AU - Counts, Scott E.

AU - Perez, Sylvia E.

AU - Kahl, Ulrika

AU - Bartfai, Tamas

AU - Bowser, Robert P.

AU - Deecher, Darlene C.

AU - Mash, Deborah C.

AU - Crawley, Jacqueline

AU - Mufson, Elliott J.

PY - 2001

Y1 - 2001

N2 - The neuropeptide galanin (GAL) is widely distributed in the mammalian CNS. Several lines of evidence suggest that GAL may play a critical role in cognitive processes such as memory and attention through an inhibitory modulation of cholinergic basal forebrain activity. Furthermore, GAL fibers hyperinnervate remaining cholinergic basal forebrain neurons in Alzheimer's disease (AD). This suggests that GAL activity impacts cholinergic dysfunction in advanced AD. Pharmacological and in vitro autoradiographic studies indicate the presence of heterogeneous populations of GAL receptor (GALR) sites in the basal forebrain which bind GAL with both high and low affinity. Interestingly, we have recently observed that GALR binding sites increase in the anterior basal forebrain in latestage AD. Three G protein-coupled GALRs have been identified to date that signal through a diverse array of effector pathways in vitro, including adenylyl cyclase inhibition and phospholipase C activation. The repertoire and distribution of GALR expression in the basal forebrain remains unknown, as does the nature of GAL and GALR plasticity in the AD basal forebrain. Recently, GAL knockout and overexpressing transgenic mice have been generated to facilitate our understanding of GAL activity in basal forebrain function. GAL knockout mice result in fewer cholinergic basal forebrain neurons and memory deficits. On the other hand, mice overexpressing GAL display hyperinnervation of basal forebrain and memory deficits. These data highlight the need to explore further the putative mechanisms by which GAL signaling might be beneficial or deleterious for cholinergic cell survival and activity within basal forebrain. This information will be critical to understanding whether pharmacological manipulation of GALRs would be effective for the amelioration of cognitive deficits in AD.

AB - The neuropeptide galanin (GAL) is widely distributed in the mammalian CNS. Several lines of evidence suggest that GAL may play a critical role in cognitive processes such as memory and attention through an inhibitory modulation of cholinergic basal forebrain activity. Furthermore, GAL fibers hyperinnervate remaining cholinergic basal forebrain neurons in Alzheimer's disease (AD). This suggests that GAL activity impacts cholinergic dysfunction in advanced AD. Pharmacological and in vitro autoradiographic studies indicate the presence of heterogeneous populations of GAL receptor (GALR) sites in the basal forebrain which bind GAL with both high and low affinity. Interestingly, we have recently observed that GALR binding sites increase in the anterior basal forebrain in latestage AD. Three G protein-coupled GALRs have been identified to date that signal through a diverse array of effector pathways in vitro, including adenylyl cyclase inhibition and phospholipase C activation. The repertoire and distribution of GALR expression in the basal forebrain remains unknown, as does the nature of GAL and GALR plasticity in the AD basal forebrain. Recently, GAL knockout and overexpressing transgenic mice have been generated to facilitate our understanding of GAL activity in basal forebrain function. GAL knockout mice result in fewer cholinergic basal forebrain neurons and memory deficits. On the other hand, mice overexpressing GAL display hyperinnervation of basal forebrain and memory deficits. These data highlight the need to explore further the putative mechanisms by which GAL signaling might be beneficial or deleterious for cholinergic cell survival and activity within basal forebrain. This information will be critical to understanding whether pharmacological manipulation of GALRs would be effective for the amelioration of cognitive deficits in AD.

KW - Alzheimer's disease

KW - Galanin

KW - Galanin receptors

UR - http://www.scopus.com/inward/record.url?scp=0035727665&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035727665&partnerID=8YFLogxK

M3 - Article

C2 - 11830760

AN - SCOPUS:0035727665

VL - 7

SP - 445

EP - 470

JO - CNS Drug Reviews

JF - CNS Drug Reviews

SN - 1080-563X

IS - 4

ER -